Publications by authors named "A Scott Kavanaugh"
The current field survey describes the identities, training, practices, and careers of 351 U.S. forensic psychologists.
View Article and Find Full Text PDFPurpose: This cross-sectional study investigates the utility of the quantitative ultrashort echo time (UTE) adiabatic T (UTE-Adiab-T) magnetic resonance imaging (MRI) in detecting potential differences in Achilles tendons and entheses of patients with psoriatic arthritis disease (PsA) compared with asymptomatic volunteers.
Material And Method: The Achilles tendons of forty-four PsA patients (59 ± 15 years old, 38 % female) and thirty-seven asymptomatic volunteers (32 ± 10 years old, 51 % female) were scanned on a 3 T clinical scanner in the sagittal plane using a 3-inch surface coil. The 3D UTE-Adiab-T sequences with fat saturation (FS) were used to measure UTE-Adiab-T.
Management of FSHD symptoms: current assistive technologies and pharmacological approaches.
Disabil Rehabil Assist Technol
November 2024
Background: Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetically linked disorder characterized by the progressive deterioration of muscles controlling facial and scapular movement. The severity and distribution of affected muscle groups vary significantly across patient demographics, necessitating diverse assistive approaches.
Objective: This review aims to evaluate the effectiveness of assistive devices and therapeutic options, including medications and rehabilitative therapies, tailored to specific manifestations of FSHD.
Article Synopsis
- Deucravacitinib is a new oral medication that selectively inhibits a protein involved in inflammatory processes, showing better results than a placebo in treating psoriatic arthritis during a phase 2 clinical trial.
- In the trial, 203 patients were split into three groups: one received a placebo, while two groups received different doses of deucravacitinib. The study measured how many patients met the criteria for a state called "minimal disease activity" after 16 weeks.
- Results indicated that more patients taking deucravacitinib achieved the necessary criteria for individual components of minimal disease activity compared to those on placebo, showing that the treatment was effective over the 16-week period.
Objectives: Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA.
Methods: FOREMOST (NCT03747939) was a phase 4 multicentre, randomised, double-blind, placebo-controlled trial.